SMS Pharmaceuticals Q2FY27 PAT Up 57% To ₹40 Crore On 30% Revenue Growth
SMS Pharmaceuticals reported Q2FY27 results with revenue up 30% YoY to ₹316 crore and PAT up 57% YoY to ₹40 crore. EBITDA margin expanded to 21%. The company expects FY27 revenue and EBITDA margins to exceed guidance. Its ₹280 crore capex program is on track, and the Peptides R&D facility is operational.
The strong financial performance, exceeding guidance, and significant progress in R&D and capex are material developments that are likely to positively influence investor perception and the company's stock performance.
The company reported significant year-on-year growth in revenue, EBITDA, and PAT, exceeding expectations and providing an optimistic outlook for the full year. Key operational milestones like the peptides facility becoming operational and progress on capex further contribute to the positive sentiment.
SMS Pharmaceuticals Limited announced its unaudited financial results for the second quarter and half year ended September 30, 2026. The company reported a 30% year-on-year (YoY) revenue growth to ₹316.08 crore for Q2FY27, driven by strong volume growth and improved price realization. Gross margin increased to 35% and EBITDA margin expanded by 145 basis points YoY to 21%, reflecting the benefits of backward integration and operating leverage.
Profit After Tax (PAT) surged by 57% YoY to ₹40 crore for Q2FY27, with PAT margin at 13%. For the half year ended September 30, 2026 (H1FY27), revenue grew 19% YoY to ₹523.05 crore, and PAT increased by 36% YoY to ₹59.76 crore.
The company completed 6 DMF/CEP filings in FY27 to date and is on track to meet its full-year target of 10 filings. Six to eight new molecules from the R&D pipeline are targeted for commercial production commencing in FY28. The ₹280 crore capital expenditure program remains on track for completion by FY27, with ₹160 crore deployed to date.
The Peptides R&D facility is now fully operational, with pilot scale production targeted for Q4FY27. The company also established SMS coLab Private Limited as a dedicated CDMO platform for APIs and peptides.
Commenting on the performance, Mr. P. Vamsi Krishna, Executive Director, stated, "We delivered a strong second quarter that exceeded our expectations." The company is confident of exceeding its earlier full-year guidance based on its H1FY27 performance and positive outlook.
What to do with a filing like this
SMS Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by SMS Pharmaceuticals Limited. Read the original for the full detail.